Business Wire

Surge of Shareholders Joins The Committee to Restore Nymox Shareholder Value, Deluge Website with Emails Expressing Dissatisfaction with NYMOX Leadership

8.8.2023 17:00:00 EEST | Business Wire | Press release

Share

The Committee to Restore Nymox Shareholder Value, LLC (CRNSV), with a goal to recover shareholder value in NYMOX PHARMACEUTICAL CORP ("NYMX-F"; Company), reports an overwhelming response by current Nymox shareholders large and small to join CRNSV via a fully dedicated website https://www.crnsv.com/.

In the interest of transparency, CRNSV shares these excerpts from some of the emails received from shareholders worldwide and remains mindful of protecting the sender’s identity and contact information.

  • Chris – Your transparency is much appreciated, especially after years of little to no communication from a company that I’ve invested a lot of money in, that has left us shareholders in the dark. I’ve got calls in to a bunch of other shareholders, some who could be very influential. Let’s plan on reconnecting.
  • Hi Chris -- I also cannot grasp the thought process of PA (CEO Averback) on how he possibly thinks he is going to get this to market with no money. I have 519,000 shares and a lot of money tied up in this because I believe in the product. I am in disbelief that a company can be run so poorly. I hope something can be resolved with this.
  • Mr. Riley -- I was aware that all was not well at the Company but was not privy to the details. I had surmised that you might be able to raise the funding needed to get the company’s lead product to market and am sorry that you apparently suffered the same fate as the previous CFO. From the outside looking in, it seems as though the product has great merit; shameful that a bad executive can thwart that opportunity for everyone.
  • Chris, I’ve seen your postings re: Nymox. As a long-term shareholder with 150,000+ shares, I am as frustrated as yourself and the others. Thoughts on how we could collectively compel Paul to another path of action? I get the sense that the FDA filing is likely a bust at this point and that they knew from years ago that it likely would be. Thanks for driving this effort.
  • Chris -- I am a 68-year-old retiree, living on a monthly SS Benefit only, and the $10,000 I invested in this company 6 years ago is now worth $1000. It’s a mere pittance to most people, but believe me, it would make my remaining years much easier if this company finally did what it said it was capable of doing all those years ago. Thank you!
  • Chris -- Dr A appears in no hurry to keep shareholders updated or to get Flex approved and commercialized. Large Shareholders who have supported Nymox with cash may no longer provide cash due to their interest in the potential partner’s proposal.

JOIN US TODAY!
All long-suffering Nymox shareholders, regardless of the size of their holdings, are invited to join the rapidly growing coalition by visiting the website https://www.crnsv.com/ and signing up for further updates. There is no obligation to join or support required and all personal contact information and identification will be confidential and protected. CRNSV will contact each shareholder to confirm participation and support for the changes called for in Nymox.

About The Committee to Restore Nymox Shareholder Value, LLC (CRNSV)
CRNSV was formed by former executives of the NYMOX PHARMACEUTICAL CORP ("NYMX-Q") with a goal to restore shareholder value in NYMOX (the Company). With a commitment to overcome the steep decline and volatility of the stock price following the catastrophic NASDAQ Delisting Decision, CRNSV has issued rebuttal letters to all Company shareholders and continues to emphasize lack of Company leadership, inability to realize the potential for valuable and promising results through a relationship with a highly respected global healthcare and specialty pharmacy solutions company with expertise to help commercialize the Company’s Benign Prostatic Hyperplasia (BPH) product, and Nymox’s lack of solution or plan for financial recovery of shareholder value. Headquartered in Carson City, Nevada with offices in London, CRNSV documents are available at https://www.crnsv.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chris Riley
info@crnsv.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release

ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release

BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol

MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments31.8.2026 16:36:00 EEST | Press release

MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831401493/en/ MEX Exchange, part of MultiBank Group, Announces Senior Leadership Appointments with David Ogg appointed Vice Chairman and Brian Andreyko named CEO. David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going on to establish LavaFX and Ogg Trading. His career has also incl

Rimini Street Announces Stock Repurchase and Debt Reduction Transactions31.8.2026 16:00:00 EEST | Press release

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831961587/en/ Rimini Street Announces Stock Repurchase and Debt Reduction Transactions Debt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance to $43.4 million. Share Repurchases: The Company repurchased 970,566 shares of its common stock at an average price of $5.16 per share for an aggregate cost of approximately $5.0 million. “Our year-to-date share repurchases

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye